Patents by Inventor Margaret Shipp

Margaret Shipp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240117440
    Abstract: The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 11, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Bjoern CHAPUY, Donald STEWART, Tim WOOD, Margaret SHIPP, Gad GETZ, Mark MURAKAMI, Lee LAWTON, Andrew DUNFORD, Kirsty WIENAND
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS
    Publication number: 20240052428
    Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.
    Type: Application
    Filed: September 15, 2023
    Publication date: February 15, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON
  • Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 11723972
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 15, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Fundacion Sales
    Inventors: Margaret Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
    Patent number: 11673956
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 13, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
    Patent number: 11446309
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS
    Publication number: 20210100813
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: July 16, 2020
    Publication date: April 8, 2021
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok Kin Wong, Zhao Chen
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20210095035
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 1, 2021
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1
    Patent number: 10844126
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • CLASSIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20200270702
    Abstract: Disclosed are methods and reagents for diagnosis, classification and treatment of DLBCL and subtypes thereof by means of gene expression profiling. Provided herein is a gene expression signature for use in obtaining diagnostic information for DLBCL and subtypes thereof. Aspects of the present disclosure relate to use of gene expression signature corresponding to particular subtype for classification of a sample from a subject and stratification of a subject for subtype-targeted clinical trial. Also provided herein is a computer based classification model for use in the methods disclosed herein.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 27, 2020
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Stefano MONTI, Daniel GUSENLEITNER, Margaret SHIPP, Bjoern CHAPUY
  • COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1
    Publication number: 20200093920
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 26, 2020
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego O. Russo, Mariana Salatino
  • Anti-galectin-1 monoclonal antibodies and fragments thereof
    Patent number: 10519238
    Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: December 31, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 10456465
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • THERAPEUTIC TREATMENT OF SELECT DIFFUSE LARGE B CELL LYMPHOMAS EXHIBITING DISTINCT PATHOGENIC MECHANISMS AND OUTCOMES
    Publication number: 20190292602
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Bjoern Chapuy, Margaret Shipp, Chip Stewart, Andrew Dunford, Gad Getz
  • COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF IMMUNE DISORDERS USING GALECTIN-1
    Publication number: 20190212330
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 11, 2019
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20190127473
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 2, 2019
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • COMPOSITIONS AND METHODS FOR THE MODULATION OF DNA DAMAGE RESPONSES USING BAL1 AND BBAP
    Publication number: 20180223288
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 9, 2018
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
    Patent number: 9939428
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 10, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
    Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Compositions and methods for the modulation of DNA damage responses using BAL1 and BBAP
    Patent number: 9840708
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: December 12, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • CLASSIFICATION OF MYC-DRIVEN B-CELL LYMPHOMAS
    Publication number: 20170029904
    Abstract: Methods for diagnosing Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) based on a diagnostic score, as well as determining MYC activity levels and selecting treatments based on a MYC activity score.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Inventors: Scott J. Rodig, Christopher Daniel Carey, Margaret A. Shipp, Stefano Monti, Daniel Gusenleitner, Bjoern Chapuy